The global beta-lactam and beta-lactamase inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Beta-lactam antibiotics are a class of antibiotics consisting of all antibiotic agents that contain a beta-lactam ring in their molecular structures. This includes penicillin derivatives, cephalosporins, monobactams, and carbapenems. These are the antimicrobial substances or compounds that fight against bacterial infections and sometimes with protozoan infections. In addition, these medications either kill the bacteria directly or stop the bacteria from growing. Furthermore, there are many new drugs in the pipeline, which are expected to be launched during the forecast period and will create an opportunity for the global beta-lactam and beta-lactamase inhibitors market players.

The major factors that propel the growth of the global beta-lactam and beta-lactamase inhibitors market include the increased consumption in low- and middle-income countries (LMICs), and the rise in prevalence of infectious diseases. In addition, the development of novel approaches for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections and a large number of clinical trials further drive the market growth. In addition, the discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players during the forecast period, and hence increase the global beta-lactam and beta-lactamase inhibitors market share.

The global beta-lactam and beta-lactamase inhibitors market analysis includes some of the key market players such as Abbott Laboratories, Allergan Plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Merck & Co. Inc., and Novartis International AG (Sandoz), among others. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Abbott Laboratories, Allergan Plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Merck & Co. Inc., and Novartis International AG (Sandoz), among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Beta-Lactam and Beta-Lactamase Inhibitors Market by Segment

By Drug Class 

• Penicillin

• Cephalosporin

• Carbapenem

• Monobactam

• Combination

By Disease 

• Urinary Tract Infection

• Respiratory Infection

• Skin Infection

• Complicated Urinary Tract Infection (cUTI)

• Complicated Intra-Abdominal Infections (cIAI)

• Nosocomial Pneumonia

• Blood Stream Infection

• Other

By Route of Administration 

• Oral

• Intravenous

• Other

Global Beta-Lactam and Beta-Lactamase Inhibitors Market by Regional Analysis